- BNF:
- Immune system and malignant disease
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- None
Comments
DO NOT PRESCRIBE (DNP): NICE TA239: Breast cancer (metastatic). Not recommended post-menopause in oestrogen dependent metastatic disease, or if disease returned/worsened after anti-oestrogens (decision date - January 2012)
DO NOT PRESCRIBE (DNP)6: NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen receptor positive breast cancer. (Decision date - February 2018)
RED:1,2 hospital use only
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again